Drug Trial Radar · NCT06858878
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,105
Actual
Start
Mar 17, 2025
Primary completion
Jan 21, 2027
Study completion Apr 16, 2027
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Conditions
- Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Interventions
Maridebart cafraglutideDrug
Maridebart cafraglutide will be adminstered SC.
PlaceboDrug
Placebo will be adminstered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body Weight at Week 72Time frame: Baseline and Week 72
Locations
187 sites in 13 countries. Site status is shown where the registry gives one.
Alliance for Multispecialty Research Mobile
Mobile, Alabama
Gilbert Center for Family Medicine
Gilbert, Arizona
Desert Clinical Research
Mesa, Arizona
Avacare Foothills Research Center
Phoenix, Arizona
San Fernando Valley Health Institute
Canoga Park, California
Core Healthcare Group
Cerritos, California
Velocity Clinical Research Chula Vista
Chula Vista, California
Headlands Research California
Escondido, California
Paradigm Clinical Research
Modesto, California
Flourish Research
Northridge, California
University of California Irvine
Orange, California
Empire Clinical Research
Pomona, California
Infinity Clinical Trials
San Diego, California
Greenwich Clinical Trials
Riverside, Connecticut
Indago Research and Health Center
Hialeah, Florida
Optimus U Corporation
Miami, Florida
New Horizon Research Center
Miami, Florida
San Marcus Research Clinic Inc
Miami Lakes, Florida
Florida Institute for Clinical Research
Orlando, Florida
Encore Medical Research of Weston LLC
Weston, Florida
Conquest Research - Winter Park
Winter Park, Florida
Alliance For Multispecialty Research - Oak Brook
Oak Brook, Illinois
Alliance for Multispecialty Research, LLC - Park Ridge
Park Ridge, Illinois
Endeavor Health Medical Group - Endocrinology and Diabetes- Skokie
Skokie, Illinois
Indiana Medical Research Institute
Merrillville, Indiana
Iowa Diabetes Research
West Des Moines, Iowa
Alliance for Multispecialty Research Newton
Newton, Kansas
Alliance for Multispecialty Research LLC
Wichita, Kansas
Advanced Internal Medicine
Paducah, Kentucky
Ima Clinical Research- Monroe
Monroe, Louisiana
Annapolis Internal Medicine, LLC
Annapolis, Maryland
Brigham and Womens Hospital
Boston, Massachusetts
International Diabetes Center - HealthPartners Institute
Minneapolis, Minnesota
Alliance for Multispecialty Research - Kansas City
Kansas City, Missouri
Palm Research Center Inc
Las Vegas, Nevada
Vector Clinical Trials
Sparks, Nevada
Premier Research
Trenton, New Jersey
Albany Medical College
Albany, New York
Asheville Clinical Research
Asheville, North Carolina
Physicians East
Greenville, North Carolina
Showing 40 of 187 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.